AstraZeneca (AZN) stock price has seen a hike due to positive reports from their new coronavirus vaccine clinical trial. At the same time, Moderna Stock (MRNA stock) has gone down following their supply deal.
On Friday, UK based AZN released a public notice regarding their authorization for final phase coronavirus vaccination applicants received from the US Food and Drug Administration. However, the prices of Johnson and Johnson (J&J) stocks soared higher on Monday after they announced the launch for 3rd phase trials for coronavirus vaccine.
There was a brief suspension in the trial process conducted by J&J and AZN since a trial candidate fell extremely ill. So, after AZN stopped their trials on September 6, with the permission to restart their final phase trial from UK officials, they resumed it on September 12. On Friday, AZN also mentioned conducting final trials in Japan, South Africa, and Brazil.
Monday’s AZN report on coronavirus vaccine, AZD1222, being tested on senior citizens. They announced that people most vulnerable to COVID-19, like old people, have shown affirmative progress and developed safe immunogenicity. AZD1222 is being processed by AZN in collaboration with Oxford University.
The Anticipation of Phase 3 Results from MRNA Stock, AZN, and Pfizer
AZN-Oxford group has been leading in the coronavirus vaccine trial until the pause on September 6. In fact, they were the first to begin the final phase of clinical trials within the month of July.
MRNA stock and the collaborating team of BioNTech (BNTX) and Pfizer (PFE) had initiated their phase 3 trial towards the fag end of July.
The current scenario shows MRNA stock and Pfizer leading the development of vaccination for COVID-19. These two companies are gearing up to issue the data regarding the final phase trial. They are also hoping to receive authorization from the US FDA within this very year, proving a successful vaccine trial.
MRNA Stock Nearing the Point of Buy
On Monday, MRNA stock sealed its deal to supply mRNA-1273 to Qatar without releasing their terms and conditions.
MRNA stock notified the completion of 30,000 enrolled participants for their final medical trial phase, last Thursday. On that day their share prices saw an increase of 3.6%.
On October 13, their stocks witnessed their quarterly highest at 81.37 after their peak of 95.21 in July.
Stock Rating
The Relative Strength (RS) of MRNA stock is 97, while AZN’s is only 45.
J&J is lagging behind MRNA Stock, Pfizer, and AZN in the entire trial process. They await their final phase results at the beginning of 2021, just like Novavax (NVAX), another firm developing coronavirus vaccine and currently conducting 3rd phase trials.
